Transient hypothyroidism after iodine-131 therapy for Grave's disease by Gómez, Núria et al.
apy, its incidence and characteristics are not well known
(5). Recurrent as well as late permanent hypothyroidism
have been described in patients with previous transient
hypothyroidism(6), butnoeffectivemeanstopredictitare
well known.
We undertook this study to: (a) characterize transient
hypothyroidism after â€˜@â€˜itherapy for Grave's disease, (b)
seek predictive factors of transient hypothyroidism before
â€˜@â€˜itherapy, (c) differentiate transient hypothyroidism
from permanent hypothyroidism at the time of diagnosis
and (d) assess the predictive value of transient hypothy
roidismin long-termthyroidfunction.
MATERIALSAND MEIHODS
From 1979to 1991,3fl patientsunderwenttherapeuticâ€˜@â€˜I
treatment for Grave's disease. Due to insufficient data from fol
low-up, 17 patients were excluded from the analysis. Thus, we
report on 355 patients.
Diagnosis of Grave's disease was based on clinical features,
subnormalserumconcentrationof thyrotropin(TSH)with con
comitant increase in thyroxine (T4) or triiodothyronine levels (D)
or both. Diffusegoiter was assessedscintigraphically.
The patients(333)were treatedwithcalculatedlow doses of
â€˜@â€˜ilower than10mCi(6.6 Â±1.9 mCi)determinedby glandweight
and 131!uptakeat 2 and24 hr. The remaining22 patientswere
treated with a dose higher than 10 mCi (12.8 Â±2.9 mCi) because
of severe associated illness and/orpersistent hyperthyroidismaf
terlow dose administration.
Two hundred and seven patients (58%) were treated with an
tithyroiddrugsfor a minimumof 6 mo and 13 patients underwent
subtotal thyroidectomy as the first therapeuticoption before 131!
treatment. No patient received antithyroiddrugs after 131!ther
apy.
Follow-up
Ginical examination and T4, t3 and basal TSH measurements
wereperformedat monthlyintervalsduringthe first6 mo, at 12
mo andthenyearlyuntilpermanenthypothyroidismdeveloped.
The meanfollow-up periodwas 34.3mo (range12-145).
Withinthe first 6 mo after â€˜@â€˜Itherapy, hypothyroidismwas
diagnosed by low T4 levels regardless of TSH levels, with or
without hypothyroidsymptoms. If T4 levels laterbecame normal
andthebasalTSHlevelswerelowerthan8 mU/liter,thediagno
sin transienthypothyroidism,but when TSH levels were higher
than 8 mU/liter, the diagnosis was permanent hypothyroidism (7).
In the first6 mo, transienthyroxinereplacementwas startedin
asymptomaticpatientsandwithdrawnbefore the next therapeutic
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ince antithyroid drugs are often ineffective in inducing
long-term remission of Grave's disease, most patients with
Grave's disease requiredefinitive therapywith â€˜@â€˜Ior sub
total thyroidectomy. Iodine-131 is increasingly becoming
the treatmentof choice since it is effectiveandsafe, but
hypothyroidism is an unavoidable consequence which in
creaseswith timeafter treatment,especiallyafterhighdose
therapy (1â€”3).Some patients, however, develop transient
hypothyroidism within the first months after â€˜@â€˜Itherapy
(4). Although the diagnosticvalue of transient hypothy
roidismis to avoidunnecessarychronicreplacementher
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The hormonal pattern at the time of transient hypothy
roidismdiagnosiswas:lowT4in all40patients,low T3in
29, high basal TSH in 22, normal TSH in 15 and low TSH
in 6 (<01 mU/liter) (Fig. 1). No variable correlated with
the hormonalpatternor transienthypothyroidismduration
(datanotshown).
Hypothyroid symptoms were present in 15 patients
(37.5%) and thyroxine replacement was started (mean du
ration,2.4 mo;range,1â€”4mo).
To differentiate transient hypothyroidism from perma
nent hypothyroidism, patients who developed permanent
hypothyroidism during the first 6 mo after â€˜@â€˜Iwere com
paredwithtransienthypothyroidismpatients(Table2).No
patientwithbasalTSH higherthan45 mU/literhadtran
sient hypothyroidism. Therefore, TSH levels higher than
45 mU/literhad a 100%positivepredictivevalue for per
manenthypothyroidismin thefirstmonthsafterâ€˜s'!treat
ment.
At the 12th mo, 34 patients with transient hypothyroid
ism were euthyroid and only two of these had TSH levels











course. Patients whose hyperthyroidism relapsed were treated
with an additional131!dose.
Measurements
Total serumT4 (normalvalues 70â€”170nmole/liter),T3 (normal
values1.2â€”3nmole/liter)andTSH(normalvalues0.1â€”4mU/liter)
were measuredby specificradioimmunoassays.From 1986,hor
mone levels were determinedby enzymoimmunoassay.
Thyroid uptake of â€˜@â€˜Iat 2 and 24 hr was calculated from a
50-mCitracerdose given before the therapeuticdose.
Data AnalysIs
We analyzedthe followingvariables:sex, age, previousanti
thyroiddrugintakeandsurgicaltreatment,â€˜@â€˜Iuptakeat 2 and 24
hr, T4 and T3 levels before 131!therapy, 131!to dose-induced
transient hypothyroidism, the @â€˜Iaccumulative dose (in mCi) and
T4, T3 and basal TSH levels during transient hypothyroidism.
Data were expressed as mean Â±s.d. Variables were compared by
chi square testing and analysis of variance (SPSS program)(8).
Survival analysis of disease by the Kaplan-Meier method (9)
was performed and time-dependent variables analyzed by the
Mantel-Cox method (BMDP1L program) to describe the time
course of thyroid function after â€˜@â€˜Itherapy (10,11). Patients who
developed permanenthypothyroidismduringthe first 6 mo after
131! therapy were exluded from life-table analysis because it is not
possiblethat transienthypothyroidismdevelopedduringthe same
period. To predict risk factors for developing transient hypothy
roidism, patients were distributedinto categories of exposure for
each variable, and the Odds ratiowas estimatedwith a multivari
ate statistical model by conditional logistic regression using the
likelihood ratio method (EGRET program).
RESULTS
Ofthe333patientstreatedwithcalculatedlow dosesof
â€˜@â€˜i,transient hypothyroidism was diagnosed in 40 (29
women, 11men, aged 28â€”71yr; mean, 48.8 yr). Twenty-six
patientsdevelopedtransienthypothyroidismafterthefirst
dose of 131!,nine after the second and two after the third.
Three patients developed transient hypothyroidism twice
(two patients after the first and second 131!doses and a
thirdafterthe secondandfourthâ€˜i'!doses), makingthe
total number of transient hypothyroidism episodes 43.
Transienthypothyroidismwas not diagnosedafter high
dosetherapy.No differenceswereobservedinclinicaland
laboratory findings at the time of â€˜@â€˜Itherapy or in thyroid
function after 131!administration between patients treated
with low and high doses (data not shown).
Patientswithandwithouttransienthypothyroidismwere
comparedtopredictthedevelopmentof transienthypothy
roidism (Table 1). Pretreatment T4 and T3 levels and â€˜@â€˜I
uptake at 2 hr postadministrationwere higher in the tran
sient hypothyroidism group. After multivanate statistical
analysis, only â€˜@â€˜iuptake higher than 70% at 2 hr was a
significant risk factor for developing transient hypothyroid
ism (Oddsratio2.8, confidenceinterval0.9â€”9.4),with a
positive predictive value of 28.1% and a negative predic
tivevalueof 89.7%.
The time of diagnosis of transient hypothyroidism was
2.1 Â±1 mo after â€˜@â€˜I(range 1â€”6mo). Recovery of thyroid























FIGURE 1. T4, T3 and TSH levelsat diagnosisof transienthy
pothyroklismandat thetimeof recoveryof thyroidfunction.The
horizontaldashed line representsthe normalrange of T4 (70-160
nmole/lfter),T3 (1.2-3 nmole/Iiter)andthe upperlimitrangeof basal
TSH(0.1-4mU/liter).
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ables.
between4 and8 mU/literwhichhadnormalizedinthenext
treatment course with no thyroxine replacement. In the
remaining six patients, hyperthyroidism relapsed during
thefirst6 moaftertransienthypothyroidismdiagnosis.No
differences were observed during 131!therapy or transient
hypothyroidismbetween patientswho relapsed and those
who became euthyroid after diagnosis of transient hypo
thyroidism(datanot shown).
Life-table analysis showed an 81.4% risk of permanent
hypothyroidism 141 mo after â€˜@â€˜Itherapy for patients who
previously developed transient hypothyroidism versus
89.9% for patients without transient hypothyroidism
(p = 0.64) (Fig. 2). TSH levels at the onset and end of
transient hypothyroidism did not correlate with the prob
ability of late-onset permanent hypothyroidism (p = 0.53).
DISCUSSION
The incidenceof transienthypothyroidismin patients
treated with low-dose radioiodine was 12.1% and has been
reported to range from 3.8% to 28% (5,6,12â€”16).These
variations may result not only from differences in follow-up
andtheadministeredâ€˜@â€˜Idosebutalsofromthe imprecise
definition of transient hypothyroidism in many reports.
Our series included patients diagnosed with transient hy
pothyroidismif T4 levels were low, regardlessof basal
TSH in the first months after â€˜@Itherapy, followed by T4
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roidism.The horizontaldashed line represents the median prObabII
OiLyofpermanenthypothyroidism.
1.1Â±0.4 1.1Â±0.6 ns
13.3 Â±10.6 44.9 Â±33.9 0.001 mU/liter during the next few months. TSH levels at the
time of the transient hypothyroidism diagnosis were cx
cludedfromdiagnosticcriteriabecauseof the slow recov
cry of TSH secretion after long-term suppression in thyro
toxic patients (4,17â€”20).We found that transient
hypothyroidismdevelopedwithinthe first6 mo and disap
pearedwithin the firstyear after â€˜@â€˜Itherapy. Patientswith
basal TSH levels between 4 and 8 mU/liter after recoveiy
of peripheralthyroidfunctionwere includedin the analysis
since these levels normalized spontaneously. In contrast,
patientswithhighbasalTSHlevelswhoweretreatedwith
â€˜@â€˜ishould be considered as having permanent hypothy
roidism (4â€”6,14,16,19).
Transienthypothyroidismdid not developin those pa
tientswithGrave'sdiseasewhoreceived131!dosesgreater
than10mCi.Thisfactormaybe relatedto thesmallnum
berof patientsincludedin thisgroup(n = 22);however,
transienthypothyroidismhas not been describedin pa
tients who received high doses of â€˜@â€˜I(1â€”3).
After multivariate statistical analysis, the only signifi
cant risk factor for developing transient hypothyroidism
was â€˜@â€˜Iuptake at 2 hr higher than 70% before therapy.
This should be considered a negative risk factor because of
thelowpositivepredictivevalue(28.1%)andhighnegative
predictivevalue(89.7%).
Themainproblemin clinicalpracticeis to differentiate
transient hypothyroidism from permanent hypothyroidism
in the early months after therapy. We found that TSH
levels higher than 45 mU/liter were a predictive factor for
permanent hypothyroidism, with a specificity of 100%.
According to some authors, transient hypothyroidism is
a centralhypothyroidismphase duringrecoveryof the
hypothalamic-pituitary axis after â€˜@â€˜Itreatment (21 ). Our
resultsdo not supportthis hypothesissince basal TSH
levels were high (51%),normal (35%)or low (14%)at the
onset of transienthypothyroidismand the time of recovery
of thyroidfunctiondidnotcorrelatewithinitialTSHlevels.
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Moreover, transient hypothyroidism is not present in other
hyperthyroidal etiologies with proven pituitary suppres
sion aftertherapy(22). In contrast,otherauthorssuggest
thatprevioustreatmentwithantithyroidrugsmayinduce
intrathyroidaliodinedepletionand, after â€˜@â€˜Itherapy,a
reductionin the entrapmentof iodineby the glandmay
impair the maintenance of thyroid hormone production
(23). In our study, antithyroid pretreatment was not asso
ciatedwith developmentof transienthypothyroidism.Fi
nally, transient hypothyroidism may be immunomediated
by TSH receptor antibodies, which may account for the
specificity of transient hypothyroidism in Grave's disease.
Thus, â€˜@â€˜Itherapywould cause diffuse thyroiddamageand
a simultaneousrise in thyrotropinreceptorantibodies
(24-27), which may be blockers. This analysis was not
possibleinourseriesbecausemanyof thepatientsdidnot
have these antibodies. The outcome for patientswith tran
sienthypothyroidismisnotwellknown(5,416).Recurrent
hyperthyroidismhas been described(416) andwas also
diagnosed in six of our patients. Analysis by the Mantel
Cox method showed that residual thyroid function did not
differfrom that of patients without previous transient hy
pothyroidismand was independentof TSH levels during
transienthypothyroidism.
CONCLUSION
Transient hypothyroidism developed in 12.1% of pa
tients treated with low-dose 131!for Grave's disease during
the firstyear afterâ€˜@â€˜Itherapyandwas asymptomaticin
most patients. Transient hypothyroidism did not develop
afteradministrationof doses higherthan 10 mCi. Transient
hypothyroidism was not a central hypothyroidism since
TSH levels were high, normal or low at transient hypothy
roidismonset and did not correlatewith the time of recov
cry. Therewas no prognosticfactorto reliablypredict
transient hypothyroidism before â€˜@â€˜Itherapy or at the time
of diagnosis. TSH levels higher than 45 mU/liter ruled out
transienthypothyroidism.Inview of ourfindings,thepos
sibiity of spontaneousrecoveryof thyroidfunctionshould
be considered before making a diagnosis of definitive hy
pothyroidismwithin the first months after â€˜@â€˜Itherapy,
particularly if TSH levels are lower than 45 mU/liter. Con
sequently, we recommend later assessment of thyroid
function, for example, 6 mo after â€˜@â€˜Itherapy, because at
that time all of our patientswith transient hypothyroidism
had recoveredtheirthyroidfunction.Althoughtransient
hypothyroidismwas not a prognostic index future thyroid
function, its clinical significance lies in accurate diagnosis
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